Skip to content
Peptide research

MGF

Also known as Mechano Growth Factor
Category
Tissue Repair & Recovery
Administration routes
Injectable
Regulatory status
Not FDA-approved

What it is

Synthetic MGF is an E-domain fragment associated with an IGF-1 splice variant expressed by stressed muscle, marketed to speed muscle, tendon, and heart repair. The case rests almost entirely on animal and cell studies; a 2014 study found no measurable activity, calling the mechanism into question. There is no human safety data, and as an IGF-1 relative it carries a theoretical cancer risk. Supply is unregulated black-market product of uncertain purity, and it is not an approved drug.

Read Full record

Studied uses & evidence

Studied uses(7)

  • Satellite cell activation and muscle repair

    Low

    Rodent studies suggest muscle activation signals. Human evidence includes gene-expression studies and experiments in cultured human muscle cells, with contradictory results.

  • Enhanced myogenic progenitor cell transplantation

    Speculative

    Improved cell engraftment in one mouse transplantation study; not replicated or tested in humans.

  • Cardiac protection and post-infarction recovery

    Low

    Multiple rodent heart-attack studies show benefit, with a plausible mechanism, but no human trials.

Evidence limits

Evidence Level
Preclinical

All MGF research to date is preclinical, conducted in cell cultures, rodent models, and one sheep cardiac model. No controlled human clinical trials have been conducted. Results are mixed: some labs report robust effects on satellite cell activation and cardiac protection, while a well-powered 2014 study found no significant effects on myoblasts or primary muscle stem cells. The existence of endogenous E-peptide processing in vivo has not been confirmed despite mRNA detection.

Benefits = confidence in the evidence: High · Medium · Low · Speculative (High requires human randomized trials for that specific benefit)

Cautions & risk summary

Do not use if

  • Active cancer

    High

    MGF is a splice variant of IGF-1. Growth factor activity may promote tumor proliferation.

General cautions

  • Pregnancy

    Absolute

    No safety data. Growth factor signaling during fetal development is unpredictable.

Risk summary(10)

Risks = level of concern: High · Moderate · Low · Theoretical

  • No human safety data exists — all evidence is preclinical

    High
  • Endogenous E-peptide processing has never been confirmed in vivo despite mRNA detection

    Moderate
  • Major 2014 study found zero biological activity in multiple cell types, questioning the entire MGF hypothesis

    High
  • Illegal MGF analogs of unknown purity and properties are sold on the black market with potentially serious side effects

    High
  • As an IGF-1 splice variant, theoretical oncogenic risk exists — IGF-1 signaling is implicated in cancer proliferation

    Theoretical
  • MGF peptide may aggregate at physiological pH, making bioavailability and actual dose uncertain

    Theoretical
  • Injection site reactions (pain, swelling, redness) reported anecdotally

    Low
  • Potential hypoglycemia risk given IGF-1 family membership, though not directly documented for MGF

    Theoretical
  • Long-term effects of exogenous MGF administration are completely unknown

    High
  • No standardized manufacturing or quality control for commercially available MGF products

    High
Safety & interactions in Full record

Further reading

Read Full record

This is educational content compiled from published research, not medical advice. Always consult a licensed healthcare provider before using any peptide. Medical disclaimer

Compiled from published research indexed through March 2026.